TO THE EDITOR: We read with interest the publication by van Poppelen et al. 1 The authors analyzed 30 iris melanomas (also known as anterior uveal melanomas) and 7 iris nevi by massively parallel sequencing analysis of multiple genes (GNAQ, GNA11, EIF1AX, SF3B1, BAP1, NRAS, BRAF, PTEN, KIT, TP53, and the TERT promoter) known to be mutated in cutaneous and posterior uveal (ciliary and choroidal) melanoma. Chromosomal copy number alterations were determined by sequencing, fluorescence in situ hybridization, or single nucleotide polymorphism arrays and BAP1 immunohistochemistry was also performed. The authors concluded that the mutations they identified in iris melanomas suggest these tumors have a molecular profile comparable with both cutaneous and posterior uveal (ciliary and choroidal) melanoma.
Van Poppelen et al 1 identified many mutations seen in posterior uveal melanomas, including activating GNAQ and GNA11 (Q209 or R183) mutations in most samples (79%; 28 of 37 samples). Additionally, EIF1AX, SF3B1, and BAP1 mutations were identified in 6 (16%), 2 (5%), and 16 (43%) of the 37 samples, respectively. These mutations are all exceedingly rare in cutaneous melanomas 2 and support iris melanomas being related to posterior uveal melanomas. Our previous study of iris melanomas showed similar findings. Van Poppelen et al 1 also conclude that iris melanomas are genetically related to cutaneous melanoma, based on their finding mutations in BRAF, NRAS, KIT, PTEN, and TP53. The strongest argument for a genetic relationship of iris melanomas to cutaneous melanoma seems to be the occurrence of BRAF and NRAS mutations. However, the mutations identified by van Poppelen et al were BRAF D594G and NRAS A18T, D30N, A66T, E76K, A130T, S136N, G138E, and E143K mutations. These are not the activating BRAF V600 or NRAS G12, G13, or Q61 mutations commonly observed in cutaneous or conjunctival melanomas. 2, 4 Furthermore, pathogenic BRAF and NRAS mutations found in cutaneous melanomas are almost always mutually exclusive of each other and of activating GNAQ and GNA11 mutations. Many of the BRAF and NRAS mutations identified by van Poppelen et al were detected in tumors also harboring clearly activating hotspot mutations in GNAQ or GNA11. This finding also argues against the BRAF and NRAS mutations detected in these tumors being pathogenic driver mutations.
BRAF, NRAS, KIT, PTEN, and TP53 mutations are not commonly observed in posterior uveal melanoma. 5 The higher frequency of these mutations in iris melanomas (identified by van Poppelen et al) than in posterior uveal melanoma could be due to the former tumors being more exposed to ultraviolet radiation and, thus, gaining higher numbers of ultraviolet light-induced passenger mutations. Another potential contributory factor is that DNA isolated from older formalin-fixed paraffin-embedded tissue samples may be of lower quality, the sequencing of which may yield artifactual mutation calls.
In summary, the genetic data presented by van Poppelen et al 1 that argue iris melanomas are pathogenetically closely related to uveal melanoma is similar to our prior findings.
3 All mutations known to be activating were detected in GNAQ and GNA11. Additionally, the co-occurring mutations in EIF1AX, SF3B1, and BAP1 are reminiscent of the mutations seen in posterior uveal melanoma. 5 In our opinion, the nature of the other mutations identified in BRAF, NRAS, KIT, PTEN, and TP53 argues for these being nonpathogenic passenger mutations. The classification of iris melanoma as pathogenetically related to intraocular ciliary and choroidal melanoma and not to melanomas of the ocular surface and the skin could prove important for optimal management of affected patients.
